OCUPHIRE PHARMA INC. - COMMON STOCK

Ocuphire Pharma Receives PDFUA Fee Waiver for Nyxol New Drug Application from FDA

12 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Last Patient Completes Final Visit in ZETA-1 Phase 2b 24-Week Trial of Oral APX3330 in Diabetic Retinopathy

08 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Ocuphire Pharma to Present at The H.C. Wainwright 24th Annual Global Investment Conference

06 Sep 2022 08:00:01 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Financial Results for the Second Quarter 2022 and Provides Corporate Update

12 Aug 2022 06:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Upcoming Presentations at Two Conferences in August

08 Aug 2022 06:00:00 By Nasdaq GlobeNewswire

Ocuphire Extends U.S. Patent Protection for Late-Stage Drug Candidate Nyxol® for Reversal of Mydriasis by Five More Years into 2039 with New Patent Issuance

03 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Ocuphire Announces Late-Breaking Paper for Nyxol for Reversal of Dilation Indication at Annual ASRS Meeting and Five More Presentations at Conferences in July

07 Jul 2022 07:00:01 By Nasdaq GlobeNewswire

Ocuphire Granted New U.S. Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabetics and Announces New Peer-Reviewed APX3330 Publication

29 Jun 2022 08:00:37 By Nasdaq GlobeNewswire

Ocuphire to Present New Interim Masked Safety Data for Oral APX3330 in Diabetics at Annual Macula Society Meeting

08 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances

19 May 2022 06:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Financial Results for First Quarter 2022 and Provides Corporate Update

13 May 2022 07:00:01 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Upcoming Presentations at the Retina World Congress, Clinical Trials at the Summit, and the H.C. Wainwright Global Investment Conference

11 May 2022 07:00:02 By Nasdaq GlobeNewswire

Ocuphire Completes Last Clinical Trial Supporting the Planned 2022 NDA Submission with the Announcement of Positive Results from MIRA-4 Pediatric Safety Trial Evaluating Nyxol® for Reversal of Mydriasis

28 Apr 2022 06:00:01 By Nasdaq GlobeNewswire

Ocuphire Announces Upcoming Clinical Presentations at ARVO 2022 Medical Meeting and MODLive! 2022

26 Apr 2022 08:00:02 By Nasdaq GlobeNewswire

Ocuphire Appoints Jay Pepose, M.D., Ph.D., as Chief Medical Advisor and Announces Upcoming Presentations at ASCRS 2022 and Eyecelerator

19 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

Ocuphire Pharma to Present at Wet AMD & DME Drug Development Summit in Boston, MA

06 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

Ocuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis

29 Mar 2022 06:00:01 By Nasdaq GlobeNewswire

Ocuphire Announces Financial Results for the Fourth Quarter and Year Ended December 31, 2021 and Provides Corporate Update

24 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Ocuphire Completes Enrollment of Over 100 Subjects in 24-Week ZETA-1 Phase 2b Trial of Oral APX3330 for the Treatment of Diabetic Retinopathy

16 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

Ocuphire Pharma to Present at Oppenheimer Annual Healthcare Conference

10 Mar 2022 08:27:42 By Nasdaq GlobeNewswire